Pharmaceutical intelligence for consultancies
Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.
With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.
What we offer
As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.
We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.
How it helps
Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:
By Ian Schofield 29 Nov 2022
Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
By Jessica Merrill 14 Nov 2022
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
By Mandy Jackson 14 Nov 2022
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
By David Wallace 25 Oct 2022
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Topic Company Analysis
By Jung Won Shin 25 Oct 2022
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
21 Oct 2022
As biopharma continues to make progress developing novel and more targeted cancer therapies, regulators are responding with innovative and collaborative approaches to reviewing cancer products, aiming to resolve questions earlier and review products more quickly. Pink Sheet closely covers these programs, helping readers understand the expectations, challenges and opportunities, as well as lessons from companies putting policy into practice. This ebook takes some of our recent articles on special review mechanisms and regulators’ data expectations.
By Eleanor Malone 20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
By Amanda Micklus 20 Jun 2022
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic Cell & Gene Therapy
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: